The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
Christy M. Hebner,Bin Han,Katherine M. Brendza,Michelle Nash,Maisoun Sulfab,Yang Tian,Magdeleine Hung,Wanchi Fung,Vivian Randall W,Trenkle James D,James G. Taylor,Kyla Bjornson,Steven S. Bondy,Xiaohong Liu,John O. Link,Johan Neyts,Roman Sakowicz,Weidong Zhong,Hengli Tang,Uli Schmitz +19 more
Reads0
Chats0
TLDR
It is demonstrated that upon metabolic activation TGV is a specific, covalent inhibitor of the HCV NS5B polymerase and is mechanistically distinct from other classes of the non-nucleoside inhibitors (NNI) of the viral polymerase.Abstract:
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B polymerase region. TGV does not inhibit NS5B enzymatic activity in biochemical assays in vitro, suggesting a more complex antiviral mechanism with cellular components. Here, we demonstrate that TGV exerts anti-HCV activity utilizing a unique chemical activation and subsequent direct interaction with the NS5B protein. Treatment of HCV subgenomic replicon cells with TGV results in a modified form of NS5B with a distinctly altered mobility on a SDS-PAGE gel. Further analysis reveals that the aberrantly migrating NS5B species contains the inhibitor molecule. Formation of this complex does not require the presence of any other HCV proteins. The intensity of the aberrantly migrating NS5B species is strongly dependent on cellular glutathione levels as well as CYP 1A activity. Furthermore analysis of NS5B protein purified from a heterologous expression system treated with TGV by mass spectrometry suggests that TGV undergoes a CYP- mediated intracellular activation step and the resulting metabolite, after forming a glutathione conjugate, directly and specifically interacts with NS5B. Taken together, these data demonstrate that upon metabolic activation TGV is a specific, covalent inhibitor of the HCV NS5B polymerase and is mechanistically distinct from other classes of the non-nucleoside inhibitors (NNI) of the viral polymerase.read more
Citations
More filters
Journal ArticleDOI
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
TL;DR: In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a molecule are summarized.
Journal ArticleDOI
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
TL;DR: Insight into the structures of these proteins and the mechanisms by which they contribute to the HCV replication cycle are reviewed, and how these insights have facilitated the development of new, directly acting antiviral compounds that have started to enter the clinic are discussed.
Journal ArticleDOI
Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
John O. Link,James G. Taylor,Lianhong Xu,Michael L. Mitchell,Hongyan Guo,Hongtao Liu,Kato Darryl,Thorsten Kirschberg,Jianyu Sun,Neil H. Squires,Jay P. Parrish,Terry Kellar,Yang Zheng-Yu,Chris Yang,Mike Matles,Yujin Wang,Kelly Wang,Guofeng Cheng,Yang Tian,Erik Mogalian,Elsa Mondou,Melanie Cornpropst,Jason K. Perry,Manoj C. Desai +23 more
TL;DR: Compound 39 (ledipasvir, GS-5885) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients.
Journal ArticleDOI
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
TL;DR: The literature associated with the metabolism of fluorinated molecules is summarized, focusing on examples where the presence of fluorine influences the metabolic profile.
Journal ArticleDOI
New horizons in hepatitis C antiviral therapy with direct-acting antivirals.
TL;DR: Future research will need to define well‐tolerated and cost‐effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Dongliang Ge,Jacques Fellay,Alexander J. Thompson,Jason Simon,Kevin V. Shianna,Thomas J. Urban,Erin L. Heinzen,Ping Qiu,Arthur H. Bertelsen,Andrew J. Muir,Mark S. Sulkowski,John G. McHutchison,David Goldstein +12 more
TL;DR: It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Journal ArticleDOI
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
TL;DR: This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed molecular studies ofHCV and the development of antiviral drugs.
Journal ArticleDOI
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
TL;DR: The addition of boceprevir to standard therapy with peginterferon–ribavirin, as com pared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection.
Related Papers (5)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
Vincenzo Summa,Steven W. Ludmerer,John A. Mccauley,Christine Fandozzi,Christine Burlein,Giuliano Claudio,Paul J. Coleman,Jillian DiMuzio,Marco Ferrara,Marcello Di Filippo,Adam Gates,Donald J. Graham,Steven Harper,Daria J. Hazuda,Carolyn McHale,Edith Monteagudo,Vincenzo Pucci,Michael Rowley,Michael T. Rudd,Aileen Soriano,Mark W. Stahlhut,Joseph P. Vacca,David B. Olsen,Nigel J. Liverton,Steven S. Carroll +24 more